Updated daily as additional research gets underway, this pipeline tracker follows the global effort to find drugs that could help treat COVID-19 and the symptoms it causes, and accelerate a vaccine that could help limit the spread of the pandemic.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
One Phase III trial hits but a second study misses by a mile.
The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.
Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.
A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.
Plus deals involving Basilea/Venatorx, CorMedix/Melinta, SERB/Y-mAbs, XOMA/Lava, XOMA/Hillevax, MaxCyte/Adicet/Anocca and Bausch Health/DURECT.
Lilly said prices governments pay in developed countries, including those in Europe, need to increase to make US drug prices lower, rebalancing costs as CEO David Ricks recently advocated.
The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.
